Orlistat Augments Postprandial Increases in Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients
Response to Damci et al.
- Michael Horowitz, MB, BS, PHD1,
- Christine Feinle-Bisset, PHD1,
- Karen Jones, PHD1 and
- Michael Nauck, MD2
- 1Department of Medicine, University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia
- 2Diabeteszentrum, Bad Lauterberg im Harz, Germany
- Address correspondence to Professor Michael Horowitz, Department of Medicine, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia, 5000. E-mail: michael.horowitz{at}adelaide.edu.au
Damci et al. (1) suggest that the lipase inhibitor, orlistat, stimulates the postprandial secretion of glucagon-like peptide-1 (GLP-1) after meals containing fat and speculate that this may lead to reductions in both postprandial glycemia and energy intake. The authors observed (in a cohort of 29 type 2 diabetic patients) that after ingestion of a 600 kcal breakfast (comprising 38% fat, 50% carbohydrate, and 12% protein), the increases from baseline in plasma GLP-1 and serum C-peptide were slightly greater and that of serum glucose slightly less, as measured in a single blood sample taken 60 min after commencement of the …
